Skip to main content
. 2022 Apr 6;6:e2100390. doi: 10.1200/PO.21.00390

FIG 2.

FIG 2.

(A) Optimal atezolizumab expansion cohort redesigns for metastatic urothelial carcinoma according to type I error and power. The red point indicates the optimal accuracy design. (B) Optimal atezolizumab expansion cohort redesigns for metastatic urothelial carcinoma according to the average sample size under the null and the average sample size under the alternative. The red point indicates the optimal efficiency design.